Clinical Trials in Phoenix

Showing 5381-5400 of 16,646 trials

Osia 2 Pediatric Expansion Study

NCT05000931

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD).Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Thus the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

Mixed Hearing LossSingle-Sided DeafnessConductive Hearing Loss

Cochlear50 participantsStarted Jan 2022

Phoenix, Arizona, United States • Palo Alto, California, United States • San Diego, California, United States +4 more locations

TERMINATEDPhase 2< 1 mile

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

NCT05602727

The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.

Alzheimer's Disease

Merck Sharp & Dohme LLC99 participantsStarted Dec 2022

Phoenix, Arizona, United States • Fullerton, California, United States • Sherman Oaks, California, United States +71 more locations

Osia 2 Pediatric Expansion Study

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

Find Trials by Condition in Phoenix

Electrophysiological Recordings from Deep Brain Stimulation Electrodes for Pain

A Phase III Trial of e-TNS for the Acute Treatment of Migraine

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

SpineJack System Postmarket Registry

Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

De-Implementation of Unnecessary Surgical Antibiotic Prophylaxis in Children

Pragmatic Trial Examining Oxygenation Prior to Intubation

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria